JP2013514365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514365A5 JP2013514365A5 JP2012544736A JP2012544736A JP2013514365A5 JP 2013514365 A5 JP2013514365 A5 JP 2013514365A5 JP 2012544736 A JP2012544736 A JP 2012544736A JP 2012544736 A JP2012544736 A JP 2012544736A JP 2013514365 A5 JP2013514365 A5 JP 2013514365A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- composition according
- cells
- effector molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 210000004185 Liver Anatomy 0.000 claims description 4
- 230000003902 lesions Effects 0.000 claims description 4
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000001394 metastastic Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 102100019461 CD28 Human genes 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 2
- 210000000447 Th1 Cells Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 102000002689 toll-like receptors Human genes 0.000 claims 2
- 108020000411 toll-like receptors Proteins 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 102100006400 CSF2 Human genes 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 238000006065 biodegradation reaction Methods 0.000 claims 1
- 230000004041 dendritic cell maturation Effects 0.000 claims 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1R,2R)-1,2-dimethanidylcyclohexane;5-fluoro-1H-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
Description
治療が成功すると、30日間でCTスキャンに、ベースラインと比べて低密度(暗黒)となる全ての腫瘍の病変の膨張を示した(大きくなる)。CT上でより大きい腫瘍の外観には、均一な低密度嚢腫または中心壊死部分と生存する進行周縁部のある進行性腫瘍とは対照的に、低密度のドット状の異種斑点が現れる。低濃度で不均一な外観は腫瘍が液化したことを示す。
結果
図1は、2009年6月に肝臓に転移性疾患のある転移性結腸直腸癌の患者(89歳)、及びFOLFOXとFOLFIRI化学療法、及びアバスチンと共にFOLFIRIのラインで治療された、冠状断像を示す。2010年6月には、進行して化学療法では難治となり、2010年9月には肝臓に11の転移性病変を抱えた。患者に対しては、3週間隔で、細胞1×107個の用量の本明細書に記載される薬剤を皮内に投与し、次に1週間後に肝臓に転移した病変の1つを冷凍アブレーションにより処置し、21日目に腫瘍内に好適な薬剤を注入し、28日目に細胞1×109細胞の静脈内IV注入を行った。
結果
図1は、2009年6月に肝臓に転移性疾患のある転移性結腸直腸癌の患者(89歳)、及びFOLFOXとFOLFIRI化学療法、及びアバスチンと共にFOLFIRIのラインで治療された、冠状断像を示す。2010年6月には、進行して化学療法では難治となり、2010年9月には肝臓に11の転移性病変を抱えた。患者に対しては、3週間隔で、細胞1×107個の用量の本明細書に記載される薬剤を皮内に投与し、次に1週間後に肝臓に転移した病変の1つを冷凍アブレーションにより処置し、21日目に腫瘍内に好適な薬剤を注入し、28日目に細胞1×109細胞の静脈内IV注入を行った。
Claims (11)
- 腫瘍一掃治療用組成物であって、
少なくとも1つの外来抗原、
少なくとも1つの1型炎症性サイトカイン、および
樹状細胞の成熟を引き起こすことが可能な少なくとも1つのエフェクター分子を含み、
前記外来抗原はTh1細胞で発現される同種抗原であり、
前記炎症性サイトカインは、IFN−ガンマ、IL−2、TNF−アルファ、TNF−ベータ、GM−CSF、IL−12のうち1つ以上から選ばれ、
前記エフェクター分子はCD40Lであり、
前記Th1細胞はCD3とCD28の表面分子が架橋結合されることによって活性化され、
前記組成物は、肝臓に転移性の病変がある患者に対して投与され、
前記組成物の使用は、腫瘍の一掃をもたらす、
腫瘍一掃治療用組成物。 - 前記エフェクター分子は免疫細胞の表面で発現される請求項1に記載の組成物。
- 前記エフェクター分子はToll(トル)様受容体(TLR)を介して信号を発信する請求項1に記載の組成物。
- 前記CD3とCD28の表面分子の架橋結合は、固定化された抗CD3モノクローナル抗体と抗CD28モノクローナル抗体で達成される請求項1に記載の組成物。
- 前記抗CD3モノクローナル抗体と抗CD28モノクローナル抗体はナノ微粒子またはミクロ微粒子上に固定される請求項4に記載の組成物。
- 前記ナノ微粒子またはミクロ微粒子は生分解性である請求項5に記載の組成物。
- 注入に適した媒体中に懸濁される請求項1に記載の組成物。
- 前記組成物は注入器に詰められる請求項7に記載の組成物。
- ウエハまたはチップ上に埋め込まれる請求項1に記載の組成物。
- 請求項1から9の何れか1項に記載の組成物を含み、治療のために使用される治療用組成物。
- 請求項1から9の何れか1項に記載の組成物を含み、下記のi)からv)
i)腫瘍の一掃
ii)Th1応答の刺激及び維持
iii)Th2応答の抑制
iv)樹状細胞の成熟
v)腫瘍の免疫回避メカニズムの不能化
の少なくとも何れかのために使用される、治療用組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28655109P | 2009-12-15 | 2009-12-15 | |
US61/286,551 | 2009-12-15 | ||
US12/967,910 | 2010-12-14 | ||
US12/967,910 US20110142887A1 (en) | 2009-12-15 | 2010-12-14 | Methods and compositions for liquidation of tumors |
PCT/US2010/060431 WO2011084451A2 (en) | 2009-12-15 | 2010-12-15 | Methods and compositions for liquidation of tumors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016006254A Division JP2016121164A (ja) | 2009-12-15 | 2016-01-15 | 腫瘍の一掃のための方法および組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013514365A JP2013514365A (ja) | 2013-04-25 |
JP2013514365A5 true JP2013514365A5 (ja) | 2017-07-27 |
JP6278597B2 JP6278597B2 (ja) | 2018-02-14 |
Family
ID=44143204
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012544736A Active JP6278597B2 (ja) | 2009-12-15 | 2010-12-15 | 腫瘍の一掃のための方法および組成物 |
JP2016006254A Pending JP2016121164A (ja) | 2009-12-15 | 2016-01-15 | 腫瘍の一掃のための方法および組成物 |
JP2018021974A Active JP6553219B2 (ja) | 2009-12-15 | 2018-02-09 | 腫瘍の一掃のための方法および組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016006254A Pending JP2016121164A (ja) | 2009-12-15 | 2016-01-15 | 腫瘍の一掃のための方法および組成物 |
JP2018021974A Active JP6553219B2 (ja) | 2009-12-15 | 2018-02-09 | 腫瘍の一掃のための方法および組成物 |
Country Status (16)
Country | Link |
---|---|
US (4) | US20110142887A1 (ja) |
EP (1) | EP2512502B1 (ja) |
JP (3) | JP6278597B2 (ja) |
KR (1) | KR101837561B1 (ja) |
CN (2) | CN105457020A (ja) |
BR (1) | BR112012014569A8 (ja) |
CA (1) | CA2786585C (ja) |
DK (1) | DK2512502T3 (ja) |
ES (1) | ES2667295T3 (ja) |
HK (1) | HK1222804A1 (ja) |
HU (1) | HUE037105T2 (ja) |
IL (1) | IL220386B (ja) |
NO (1) | NO2512502T3 (ja) |
PL (1) | PL2512502T3 (ja) |
PT (1) | PT2512502T (ja) |
WO (1) | WO2011084451A2 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE503419T1 (de) | 2004-02-20 | 2011-04-15 | Univ Florida | System zur verabreichung von konformer strahlungstherapie unter gleichzeitiger abbildung von weichem gewebe |
AU2011240752B2 (en) * | 2010-04-13 | 2016-07-28 | Immunovative Therapies, Ltd. | Methods and compositions for inhibition of Treg cells |
AU2012250807A1 (en) | 2011-05-03 | 2013-12-12 | Immunovative Therapies, Ltd. | Induction of IL-12 using immunotherapy |
US11773188B2 (en) | 2012-01-20 | 2023-10-03 | Immunophotonics, Inc | Chitosan-derived compositions |
CN108452443B (zh) | 2012-10-26 | 2021-05-18 | 优瑞技术公司 | 利用对放射疗法的生理反应的成像对治疗评估的系统 |
TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
EP3091990B1 (en) * | 2014-01-08 | 2021-05-12 | Mirror Biologics, Inc. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
EP3154577A4 (en) * | 2014-06-13 | 2018-02-14 | Aldar Bourinbaiar | Oral composition and methods for immunotherapy |
US20180000895A1 (en) * | 2015-01-09 | 2018-01-04 | Oncosec Medical Incorporated | Method for the treatment of malignancies |
TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
EP3423153B1 (en) | 2016-03-02 | 2021-05-19 | ViewRay Technologies, Inc. | Particle therapy with magnetic resonance imaging |
BR112019012061A2 (pt) | 2016-12-13 | 2019-11-12 | Viewray Tech Inc | sistemas e métodos de terapia de radiação |
US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
CN111712298B (zh) | 2017-12-06 | 2023-04-04 | 优瑞技术公司 | 放射疗法系统 |
WO2019204391A1 (en) * | 2018-04-19 | 2019-10-24 | Robert Caruso | Cryo-inactivated cancer cells for cancer immunotherapy |
US11209509B2 (en) | 2018-05-16 | 2021-12-28 | Viewray Technologies, Inc. | Resistive electromagnet systems and methods |
US20200010575A1 (en) * | 2018-07-05 | 2020-01-09 | Immunophotonics, Inc. | Semi-synthetic biopolymers for use in treating proliferative disorders |
WO2021141473A1 (ko) | 2020-01-10 | 2021-07-15 | 이뮤노바이옴 주식회사 | 신규한 락토바실러스 플란타룸 균주, 균주 유래 다당체 및 이의 용도 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
DE69636514D1 (de) * | 1995-03-17 | 2006-10-19 | Univ California | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen |
US7063960B2 (en) * | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
AU4328801A (en) * | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
JP2002174597A (ja) * | 2000-12-06 | 2002-06-21 | Fuji Xerox Co Ltd | センサ材料、センサ、生体物質の検出方法および透過光検出方法 |
US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
JP2006506987A (ja) * | 2002-06-28 | 2006-03-02 | エクサイト セラピーズ インコーポレーティッド | 自己免疫および臓器または造血幹細胞移植に関連する免疫学的欠損を有する患者における免疫レパートリー回復のための組成物および方法 |
US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
US20070243159A1 (en) * | 2003-04-30 | 2007-10-18 | Periasamy Selvaraj | Therapeutic Compositions and Vaccines By Glycosyl-Phosphatidylinositol (Gpi)-Anchored Cytokines and Immunostimulatory Molecules |
US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
ES2635868T3 (es) * | 2004-03-01 | 2017-10-05 | Immunovative Therapies, Ltd. | Método y composición de formulación de terapia celular |
US20060057127A1 (en) * | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
WO2006095330A2 (en) * | 2005-03-10 | 2006-09-14 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
-
2010
- 2010-12-14 US US12/967,910 patent/US20110142887A1/en not_active Abandoned
- 2010-12-15 KR KR1020127015365A patent/KR101837561B1/ko active IP Right Grant
- 2010-12-15 ES ES10842519.0T patent/ES2667295T3/es active Active
- 2010-12-15 CN CN201510883465.0A patent/CN105457020A/zh active Pending
- 2010-12-15 DK DK10842519.0T patent/DK2512502T3/en active
- 2010-12-15 BR BR112012014569A patent/BR112012014569A8/pt not_active Application Discontinuation
- 2010-12-15 PT PT108425190T patent/PT2512502T/pt unknown
- 2010-12-15 JP JP2012544736A patent/JP6278597B2/ja active Active
- 2010-12-15 EP EP10842519.0A patent/EP2512502B1/en active Active
- 2010-12-15 HU HUE10842519A patent/HUE037105T2/hu unknown
- 2010-12-15 WO PCT/US2010/060431 patent/WO2011084451A2/en active Application Filing
- 2010-12-15 NO NO10842519A patent/NO2512502T3/no unknown
- 2010-12-15 CN CN2010800575066A patent/CN102740874A/zh active Pending
- 2010-12-15 PL PL10842519T patent/PL2512502T3/pl unknown
- 2010-12-15 CA CA2786585A patent/CA2786585C/en active Active
-
2012
- 2012-06-13 IL IL220386A patent/IL220386B/en active IP Right Grant
-
2013
- 2013-04-04 HK HK16111070.2A patent/HK1222804A1/zh unknown
-
2014
- 2014-02-28 US US14/193,832 patent/US20140178334A1/en not_active Abandoned
-
2016
- 2016-01-15 JP JP2016006254A patent/JP2016121164A/ja active Pending
- 2016-03-29 US US15/084,206 patent/US20160206718A1/en active Pending
-
2018
- 2018-02-09 JP JP2018021974A patent/JP6553219B2/ja active Active
-
2022
- 2022-05-19 US US17/748,831 patent/US20220273784A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013514365A5 (ja) | ||
Chen et al. | CAR-macrophage: A new immunotherapy candidate against solid tumors | |
Sun et al. | ATP‐responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity | |
Xie et al. | Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen | |
Takaki et al. | Thermal ablation and immunomodulation: From preclinical experiments to clinical trials | |
Gorbet et al. | Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy | |
Khong et al. | The use of agonistic anti-CD40 therapy in treatments for cancer | |
Stephen et al. | Recent progress in the synergistic combination of nanoparticle‐mediated hyperthermia and immunotherapy for treatment of cancer | |
Liu et al. | Tumor microenvironment and immunotherapy of oral cancer | |
Curiel | Immunotherapy: a useful strategy to help combat multidrug resistance | |
Behm et al. | Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation | |
Nelson et al. | The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment | |
Lisiero et al. | The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells | |
JP2018509888A5 (ja) | ||
US20210353670A1 (en) | Nanoparticles for use as a therapeutic vaccine | |
Chen et al. | Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy | |
Liu et al. | Superior antitumor efficacy of IFN-α2b-incorporated photo-cross-linked hydrogels combined with T cell transfer and low-dose irradiation against gastric cancer | |
Li et al. | Nanomaterials enhance the immunomodulatory effect of molecular targeted therapy | |
Niedbała et al. | Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations | |
Yang et al. | Leveraging β‐Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine | |
Ridolfi et al. | Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response | |
Pieper et al. | Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models | |
Yang et al. | Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors | |
Noubissi Nzeteu et al. | Nanoparticle-based immunotherapy of pancreatic cancer | |
Choi et al. | Prospective approaches to enhancing CAR T cell therapy for glioblastoma |